Madsbad 2001

1 Treatments

Studied treatment repaglinide, 1-4 mg at mealtimes

Control treatment glipizide, 5-15 mg daily

Concomittant treatments -

2 Patients

Patients -

Inclusion criteria -

Exclusion criteria -

3 Methods

Blinding double-blind

Design -

Centers -

Geographical area -

Sizes 256/0

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
</table>

5 References